CARG-201

Functional cure for chronic HBV patients
Enables robust expression and secretion of HBV middle S and core antigens in vitro
Induces broad immune responses
Results in reduction HBV marker surface antigens by more than 2 logs in AAV model
Eliminates virus as monotherapy or in combination with standard antiviral therapy
Pre-IND meeting with the FDA held in 2019
Upon successful financing IND filing will be submitted in Q1, 2024
IND is planned to be filed with the FDA by the end of 2023